STI 1400
Alternative Names: STI-1400Latest Information Update: 28 Oct 2023
At a glance
- Originator Sorrento Therapeutics
- Developer Sorrento Therapeutics; ViralClear Pharmaceuticals
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (Parenteral)
- 30 Sep 2020 Sorrento Therapeutics and ViralClear Pharmaceuticals enters into an agreement to explore combination antibody and antiviral therapy in COVID-2019 infections
- 30 Sep 2020 Clinical trials in COVID-2019 infections in USA (Parenteral)